National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient‐centered Evaluation Assessment of Cardiac Events (PEACE)‐Retrospective AMI Study, 2001, 2006, and 2011. Issue 6 (June 2015)

• Record Type: Journal Article
• Authors: Guan, Wenchi; Murugiah, Karthik; Downing, Nicholas; Li, Jing; Wang, Qing; Ross, Joseph S.; Desai, Nihar R.; Masoudi, Frederick A.; Spertus, John A.; Li, Xi; Krumholz, Harlan M.; Jiang, Lixin
• Is Part Of: Journal of the American Heart Association. Volume 4:Issue 6(2015:Dec.)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2015-06
• Subjects: acute myocardial infarction -- quality of care -- spironolactone; Heart -- Diseases -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; Cerebrovascular disease -- Periodicals; Cardiology -- Periodicals; 616.1
• DOI: 10.1161/JAHA.114.001718
• Languages: English
• ISSNs: 2047-9980

Abstract

Abstract : Background: Spironolactone, the only aldosterone antagonist available in China, improves outcomes in acute myocardial infarction (AMI) among patients with systolic dysfunction and either diabetes or heart failure (HF). However, national practice patterns in the use of spironolactone in China are unknown. Methods and Results: From a nationally representative sample of AMI patients from in 2001, 2006, and 2011, we identified 6906 patients with either diabetes or HF and classified them into 1 of 4 groups according to their eligibility for spironolactone—"ideal"(left ventricular ejection fraction [LVEF] ≤40% and without contraindications), "contraindicated, " "not indicated" (neither ideal nor contraindicated), and "unknown indications" (LVEF unmeasured)—to determine how frequently patient eligibility for this drug is assessed in the hospital, how it is used in several groups, and to identify factors associated with the use in these groups. From 2001 to 2011, the proportion of patients whose eligibility for spironolactone was not assessed decreased (66.9% in 2001 to 32.8% in 2011). Spironolactone use significantly increased among ideal patients over this period (28.6% to 72.4%; P <0.001 for trend), but also in contraindicated patients (11.4% to 27.5%; P =0.002 for trend) and in other patients groups (not indicated: 27.5% to 38.3%; unknown indications: 21.3% to 35.1%; both P <0.01 for trend). In all 4 groups, patients presenting with HF on admission were more likely to receive spironolactone. Conclusions: Although the appropriate use of spironolactone and assessment of eligibility increased in China over the past decade, there remains marked opportunities for improvement. Clinical Trial Registration: URL:http://www.clinicaltrials.gov Unique identifier: NCT01624883.